-
-
-
-
-
-
-
AlloVir (ALVR) Appoints Cintia Piccina as Chief Commercial Officer
-
-
-
-
-
-
-
AlloVir Appoints Derek Adams, Ph.D., to Board of Directors
-
-
-
-
-
-
-
AlloVir Reports Third Quarter 2022 Financial Results
-
-
-
-
-
-
-
AlloVir (ALVR) Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir’s Posoleucel
-
-
-
-
-
-
-
FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir’s Posoleucel for the Treatment of Adenovirus (AdV) Infections in Adults and Children Post-Allogeneic Stem Cell Transpl
-
-
-
-
-
-
-
Data Presented at IDWeek™ 2021 Demonstrate that ALVR109, AlloVir’s Investigational SARS-CoV-2-Specific T Cell Therapy, Is Reactive Against a Broad Range of Variants, Including Delta
-
-
-
-
-
-
-
AlloVir Announces Data Presentations at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience
-
1,197,533 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

